Cantor Fitzgerald downgraded Tvardi Therapeutics (TVRD) to Neutral from Overweight.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVRD:
- Tvardi Therapeutics downgraded to Neutral from Overweight at Piper Sandler
- Morning Movers: Bloom Energy surges following $5B investment from Brookfield
- Why Is Tvardi Therapeutics Stock (TVRD) Down 85% Today?
- Tvardi says benefit of TTI-101 treatment not observed in REVERT trial
- Tvardi Therapeutics initiated with an Overweight at Barclays